clinical trial · NCT07547787
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Akeso·—·recruiting·n = 610
Locally Advanced Unresectable or Metastatic Gastric Cancer
brief summary
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
started
Dec 26, 2024
primary completion
Dec 31, 2030
completion
Dec 31, 2040
last updated
Apr 23, 2026
official title
An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol